UNIVEST FINANCIAL Corp Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• UNIVEST FINANCIAL Corp reduced its stake in Lantheus Holdings by 22.3%, now holding 24,882 shares valued at approximately $2.43 million.
• Lantheus has a consensus rating of "Moderate Buy" among analysts with a target price averaging $131.20, despite missing earnings and revenue estimates in its latest quarterly report.
• Insider Mary Anne Heino sold 26,066 shares of Lantheus at around $76.83 each, reducing her ownership by 7.56% to a total of 318,650 shares.

UNIVEST FINANCIAL Corp trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,882 shares of the medical equipment provider's stock after selling 7,159 shares during the quarter. UNIVEST FINANCIAL Corp's holdings in Lantheus were worth $2,428,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. Hughes Financial Services LLC bought a new position in shares of Lantheus during the first quarter valued at $81,000. UMB Bank n.a. raised its position in Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after buying an additional 381 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after acquiring an additional 633 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Lantheus by 29.3% in the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after acquiring an additional 298 shares during the period. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 2.00% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on LNTH. Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research note on Monday, June 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $131.20.

Lantheus Stock Up 1.6%

Lantheus stock traded up $1.11 during mid-day trading on Tuesday, reaching $72.57. 953,361 shares of the company's stock were exchanged, compared to its average volume of 1,008,981. The company has a fifty day moving average of $77.60 and a 200-day moving average of $87.77. The company has a market cap of $5.02 billion, a P/E ratio of 20.60 and a beta of 0.14. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a twelve month low of $69.12 and a twelve month high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same period in the prior year, the company posted $1.69 earnings per share. The company's revenue was up .8% compared to the same quarter last year. Sell-side analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.